Royalty Pharma Investments 2019 ICAV - Jan 31, 2022 Form 3 Insider Report for Epizyme, Inc. (EPZM)

Role: Director, 10%+ Owner
Signature: Royalty Pharma Investments 2019 ICAV, By: /s/ Pablo G. Legorreta, Director
Stock symbol: EPZM
Transactions as of: Jan 31, 2022
Transactions value $: $0
Form type: 3
Date filed: 2/9/2022, 03:30 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EPZM	Common Stock						22.7M	Jan 31, 2022	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects 22,666,667 shares of common stock acquired by Royalty Pharma Investments 2019 ICAV ("RPI 2019 ICAV") from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 31, 2022.
F2	This Form 3 is being filed by RPI 2019 ICAV. RP Management, LLC ("RP Management"), as the manager of RPI 2019 ICAV, and Pablo G. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") of the securities beneficially owned by RPI 2019 ICAV. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose.
F3	Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPI 2019 ICAV. As such, RPI 2019 ICAV may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act.